Abbvie stock forecast 2025 long-term AbbVie stock forecast 2025

Long-term AbbVie stock forecast 2025 models anticipate free cash flow exceeding $20 billion if management executes pipeline launches. Price target adjustments from major brokerages tend toward $190–$210 based on forward growth assumptions. The firm forecasts that as pressure from Humira biosimilars decline, Abbvie’s total top-line growth will pick up speed, rising from 8% in 2025 to 11% in 2026. Though no specifics were given, Leerink also identified three oncology pipeline candidates that would eventually contribute significantly to Abbvie’s revenue. Merck boasts more than six blockbuster drugs in its portfolio, with Keytruda being the key top-line driver. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few years. Keytruda’s sales are gaining from rapid uptake across earlier-stage indications, mainly early-stage non-small cell lung cancer. Continued strong momentum in metastatic indications is also boosting sales growth. Keytruda’s sales rose around 7% in the first half of 2025. AbbVie stock forecast 2025 estimates revenue resilience amid U.S. biosimilar pressures. Analysts project newer product sales potentially exceeding $15 billion, enough to sustain overall net profit margins near 20%.